Litifilimab
Litifilimab (BIIB059) is a humanized anti-BDCA2 IgG1 monoclonal antibody administered subcutaneously. Litifilimab can inhibit the production of type I interferons, cytokines and chemokines. Litifilimab can be used in the research of diseases such as systemic lupus erythematosus[1][2].
Product Specifications
CAS Number
2407378-48-5
Product Name Alternative
BIIB059
UNSPSC
12352203
Target
C-type Lectin-like Receptors (CTLRs) ; Transmembrane Glycoprotein
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/litifilimab.html
Purity
99.51
Solubility
10 mM in DMSO|H2O
Smiles
[Litifilimab]
Molecular Weight
(146.6 kDa)
References & Citations
[1]Cho SK, et al. Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus. Expert Opin Investig Drugs. 2023 May;32 (5) :345-353.|[2]Furie RA, et al. Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus. N Engl J Med. 2022 Sep 8;387 (10) :894-904.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
AN300165P-01 20 µL
Recombinant AGO2/Argonaute 2/EIF2C2 Monoclonal Antibody
Sign In for Pricing
View Details AN300165P-02 100 µL
Recombinant AGO2/Argonaute 2/EIF2C2 Monoclonal Antibody
Sign In for Pricing
View Details